A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

• Drug: Period 1
  
  A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
  Other Name: tafamidis (Vyndaqel)
• Drug: Period 2
  
  A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
  Other Name: moxifloxacin
• Drug: Period 3
  
  A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.

• Experimental: Period 1: 960 mg tafamidis (Vyndaqel)
  
  Intervention: Drug: Period 1
• Experimental: Period 2: 400 mg moxifloxacin
  
  400 mg moxifloxacin
  Intervention: Drug: Period 2
• Experimental: Period 3: Placebo
  
  Intervention: Drug: Period 3

Inclusion Criteria:

• Healthy, nonsmoking, male and/or female subjects of non-childbearing potential.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.
• Total body weight >50 kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
• An ALT or AST measurement >2 times the ULN.
• 12-lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec at Screening.
• Subjects at increased risk if dosed with moxifloxacin, according to the product label for moxifloxacin.
• History of risk factors of QT prolongation or torsades de pointes, congenital deafness and family history of sudden death.